Contact Us Advertise Events
The Microbiome Business & Science Briefing
Microbi meTimes
Reporting on The Latest Microbiome Business & Scientific Developments
  • Research
  • Clinical & Manufacturing
  • Finance
  • Gastrointestinal
  • GMO & Synbio
  • Gut-Brain Axis
  • Infectious Disease & AMR
  • Oncology
  • Biotics and Supplements
  • Regulatory & Policy
  • Skin Health
  • Women’s Health
    • TRENDING
    LBP-AIEC01: An Engineered Phage Therapy Aimed at a Bacterial Driver of Crohn’s Disease• Neobe Raises $6.8 Million to Break Down the Barriers That Stop Cancer Treatments From Working• MIT engineers create nanoparticles for delivering personalized cancer vaccines• MRM Health and Biocodex Establish Strategic Partnership to Strengthen Future Commercial Supply Capabilities for CORAL®-Based Medicines• Beyond the small intestine: ileo colonic delivery as the next frontier for oral therapeutics• Scientists Call for a National Microbiome “Moonshot” to Tackle Chronic Disease• LBP-AIEC01: An Engineered Phage Therapy Aimed at a Bacterial Driver of Crohn’s Disease• Neobe Raises $6.8 Million to Break Down the Barriers That Stop Cancer Treatments From Working• MIT engineers create nanoparticles for delivering personalized cancer vaccines• MRM Health and Biocodex Establish Strategic Partnership to Strengthen Future Commercial Supply Capabilities for CORAL®-Based Medicines• Beyond the small intestine: ileo colonic delivery as the next frontier for oral therapeutics• Scientists Call for a National Microbiome “Moonshot” to Tackle Chronic Disease•
    Editor's Choice /Pharma & Human Health
    Editor's Choice

    Toward Clinical Utility of Metagenomic Data: Interview with Dr Joël Doré

    BY Microbiome Times · OCT 17, 2019 · 1 MIN READ
    in X ✉
    Microbiome Times
    Related Coverage
    Prokarium: Leading the Evolution of Bacterial Immunotherapy, the Next Frontier in Cancer Treatment
    Editor's Choice

    Prokarium: Leading the Evolution of Bacterial Immunotherapy, the Next Frontier in Cancer Treatment

    SEP 28, 2026
    A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation
    Editor's Choice

    A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation

    SEP 1, 2026
    Stanford’s AI Designed Bacteriophages: Ushering in the Next Phase in IP Strategy for Phage Companies?
    Editor's Choice

    Stanford’s AI Designed Bacteriophages: Ushering in the Next Phase in IP Strategy for Phage Companies?

    AUG 10, 2026

    Sign up to our free newsletter

    The science, the funding, and the regulation — in your inbox.

    Most Read This Week

    • 1
      Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health
    • 2
      Vedanta Biosciences Receives Award from the Crohn’s & Colitis Foundation to Advance a Microbiome-Derived Therapeutic Program for Interception and Treatment of Inflammatory Bowel Disease
    • 3
      BiomX Enters Collaboration with Johnson & Johnson Innovation for Discovery of Microbiome-based Biomarkers for IBD
    • 4
      MIT engineers create nanoparticles for delivering personalized cancer vaccines
    • 5
      THE ROLE OF BIOFILMS: An Interview with Scioto Biosciences

    NEW WHITEPAPER: ORAL DELIVERY OF LIVE BIOTHERAPEUTIC PRODUCTS:

    Microbiome Times Magazine

    Reporting on The Latest Microbiome Business & Scientific Developments

    Sections
    • Pharma & Human Health
    • Finance
    • Research
    • Editor's Choice
    Company
    • Issue Archive
    Business
    • Advertise
    Stay Connected
    • LinkedIn
    • Contact
    © 2026 Microbiome Times Magazine
    Microbiome Times Forum USA

    Meet Your Next Collaborator

    San Francisco  •  October 21–22, 2026

    400+ biotech leaders, VCs and researchers gather for two days of partnering and dealmaking in the microbiome space. Free to attend for start-ups, academic innovators, investors and healthcare organisations.

    View the Program Register Free →